Acute Elevated Resistin Exacerbates Mitochondrial Damage and Aggravates Liver Steatosis Through AMPK/PGC-1α Signaling Pathway in Male NAFLD Mice

Abstract

Resistin was identified as a link between obesity and insulin resistance and is associated with many diseases in mice. Deciphering the related development and molecular mechanism is necessary for the treatment of these diseases. Previous studies have revealed that increased resistin levels are correlated with lipid accumulation and play a role in non-alcoholic fatty liver disease (NAFLD) development. However, the exact mechanisms underlying these processes remain unclear. To further clarify whether acute elevated resistin level exacerbated liver steatosis, a high-fat diet-induced NAFLD animal model was used and treated with or without resistin for 6 days. We discovered that resistin altered mitochondrial morphology, decreased mitochondrial content, and increased lipid accumulation in HFD mice. qRT-PCR and western blot analysis showed that acute elevated resistin significantly altered the gene expression of mitochondrial biogenesis and liver lipid metabolism molecules in HFD mice. Consequently, in vitro experiments verified that resistin reduced the mitochondrial content, impaired the mitochondrial function and increased the lipid accumulation of palmitate-treated HepG2 cells. Additionally, we demonstrated that resistin upregulated proinflammatory factors, which confirmed that resistin promoted the development of inflammation in NAFLD mice and palmitate-treated HepG2 cells. Signaling-transduction analysis demonstrated that acute elevated resistin aggravated liver steatosis through AMPK/PGC-1α pathway in male mice. This reveals a novel pathway through which lipogenesis is induced by resistin and suggests that maintaining mitochondrial homeostasis may be key to treatments for preventing resistin-induced NAFLD aggravation.

Key words

insulin resistance - diabetes - adipokines - obesity - metabolic syndrome - lipid metabolism

Publikationsverlauf

Eingereicht: 08. Mai 2020

Angenommen: 12. Oktober 2020

Artikel online veröffentlicht:
10. Dezember 2020

• References

• 1 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
• 2 Orlik B, Handzlik G, Olszanecka-Glinianowicz M. The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease. Postepy Hig Med Dosw 2010; 64: 212-219
• 3 American Gastroenterology Association 2002 Medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-1704
• 4 Musso G, Gambino R, Cassader M. et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649
• 5 Tana C, Ballestri S, Ricci F. et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health 2019; 26: 16
• 6 Abenavoli L, Milic N, Di Renzo L. et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22: 7006-7016
• 7 Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 134-140
• 8 Banerjee RR, Rangwala SM, Shapiro JS. et al. Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-1198
• 9 Wen F, An C, Wu X. et al. MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK/PPARα pathway in HepG2 cells. Int J Biochem Cell Biol 2018; 94: 133-145
• 10 Singhal NS, Patel RT, Qi Y. et al. Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab 2008; 295: E331-E338
• 11 Zhou L, Yu X, Meng Q. et al. Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR gamma coactivator 1 alpha pathway. Hepatology 2013; 57: 1384-1393
• 12 Kleiner DE, Brunt EM, Van Natta M. et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
• 13 Steppan CM, Bailey ST. et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
• 14 Kim KH, Lee K, Moon YS. et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252-11256
• 15 Vendrell J, Broch M, Vilarrasa N. et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12: 962-971
• 16 Baranova Ancha, Shobha J. Gowder. et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 2006; 16: 1118-1125
• 17 Hegazy M, Abo-Elfadl S, Mostafa A. et al. Serum resistin level and its receptor gene expression in liver biopsy as predictors for the severity of nonalcoholic fatty liver disease. Euroasian J Hepatogastroenterol 2014; 4: 59-62
• 18 Gierej P, Gierej B, Kalinowski P. et al. Expression of resistin in the liver of patients with non-alcoholic fatty liver disease. Pol J Pathol 2017; 68: 225-233
• 19 Pagano C, Soardo G, Pilon C. et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-1086
• 20 Jiang LL, Li L, Hong XF. et al. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol 2009; 21: 662-666
• 21 Bajaj M, Suraamornkul S, Hardies LJ. et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004; 28: 63-69
• 22 Perseghin G, Lattuada G, De Cobelli F. et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab 2006; 91: 5122-5125
• 23 Yamada T, Murata D, Adachi Y. et al. Mitochondrial stasis reveals p62-mediated ubiquitination in parkin-independent mitophagy and mitigates nonalcoholic fatty liver disease. Cell Metab 2018; 28: 588-604
• 24 Civitarese AE, Ukropcova B, Carling S. et al. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 2006; 4: 75-87
• 25 Heinonen S, Muniandy M, Buzkova J. et al. Mitochondria-related transcriptional signature is downregulated in adipocytes in obesity: a study of young healthy MZ twins. Diabetologia 2017; 60: 169-181
• 26 Ritov VB, Menshikova EV, He J. et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005; 54: 8-14
• 27 Petersen KF, Dufour S, Befroy D. et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671
• 28 Civitarese AE, Ukropcova B, Carling S. et al. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 2006; 4: 75-87
• 29 Anelli GM, Cardellicchio M, Novielli C. et al. Mitochondrial content and hepcidin are increased in obese pregnant mothers. J Matern Fetal Neonatal Med 2018; 31: 2388-2395
• 30 Pessayre D, Fromenty B. NASH: A mitochondrial disease. J Hepatol 2005; 42: 928-940
• 31 Ibdah JA, Perlegas P, Zhao Y. et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 2005; 128: 1381-1390
• 32 Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384-387
• 33 Caldwell SH, Swerdlow RH, Khan EM. et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J. Hepatol 1999; 31: 430-434
• 34 Kleiner DE, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin. Liver Dis 2016; 20: 293-312
• 35 Lotowska JM, Sobaniec-Lotowska ME, Bockowska SB. et al. Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria. World J Gastroenterol 2014; 20: 4335-4340
• 36 Neuman MG, French SW, French BA. et al. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol 2014; 97: 492-510
• 37 Wakabayashi T. Megamitochondria formation-physiology and pathology. J Cell Mol Med 2002; 6: 497-538
• 38 Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrino Metab 2011; 22: 259-265
• 39 Yagmur E, Trautwein C, Gressner AM. et al. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006; 101: 1244-1252
• 40 Bokarewa M, Nagaev I, Dahlberg L. et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795
• 41 Tsiakou AG, Tsioulos DI, Panagiotou TN. et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007; 378: 78-85
• 42 Bahr MJ, Ockenga J, Böker KH. et al. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and alteredhepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E199-E206
• 43 Li B, Fang J, Zuo Z. et al. Activation of the porcine alveolar macrophages via toll-like receptor 4/NF-кB mediated pathway provides a mechanism of resistin leading to inflammation. Cytokine 2018; 110: 357-366
• 44 Silswal N, Singh AK, Aruna B. et al. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun 2005; 334: 1092-1101
• 45 Alexes CDaquinag, Zhang Y. et al. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 2011; 9: 74-86
• 46 Sánchezsolana B, Laborda J, Baladrón V. Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol. Endocrinol 2012; 26: 110-127
• 47 Lee S, Lee HC, Kwon YW. et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 2014; 19: 484-497
• 48 Benomar Y, Gertler A, Lacy PD. et al. Central resistin overexposure induces insulin resistance through toll-like receptor 4. Diabetes 2013; 62: 102-114
• 49 Tarkowski A, Bjersing J, Shestakov A. et al. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010; 14: 1419-1431
• 50 Li Z, Wang X, Pan H. et al. Resistin promotes CCL4 expression through Toll-like receptor-4 and activation of the p38-MAPK and NF-κB signaling pathways: implications for intervertebral disc degeneration, Osteoarthr. Cartilage 2017; 25: 341-350
• 51 Gan AM, Butoi ED, Manea A. et al. Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways. Cell Tissue Res 2013; 351: 161-174